DrugPatentWatch Database Preview

Details for Patent: 8,367,102

« Back to Dashboard

Which drugs does patent 8,367,102 protect, and when does it expire?

Patent 8,367,102 protects ABSORICA and is included in one NDA.

This patent has twelve patent family members in nine countries.

Summary for Patent: 8,367,102

Title:	Pharmaceutical semi-solid composition of isotretinoin
Abstract:	An oral pharmaceutical composition of isotretinoin containing at least two lipidic excipients, one of them being hydrophilic (i.e. having an HLB value superior or equal to 10), the other being an oily vehicle.
Inventor(s):	Vanderbist; Francis (Beersel, BE), Servais; Cecile (Malonne, BE), Baudier; Phillippe (Uccle, BE)
Assignee:	Galephar Pharmaceutical Research, Inc. (Juncos, PR)
Application Number:	11/892,363
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,367,102
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Dosage form;

Drugs Protected by US Patent 8,367,102

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Sun Pharm Inds Inc	ABSORICA	isotretinoin	CAPSULE;ORAL	021951-001	May 25, 2012	BX	RX	Yes	No
Sun Pharm Inds Inc	ABSORICA	isotretinoin	CAPSULE;ORAL	021951-002	May 25, 2012	BX	RX	Yes	No
Sun Pharm Inds Inc	ABSORICA	isotretinoin	CAPSULE;ORAL	021951-005	Aug 15, 2014		RX	Yes	No

Foreign Priority and PCT Information for Patent: 8,367,102

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Belgium	2000/0111	Sep 22, 2000

International Family Members for US Patent 8,367,102

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	270544
Australia	8943801
Brazil	102013032172